Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2003 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00003437
First received: November 1, 1999
Last updated: December 3, 2013
Last verified: February 2003
  Purpose

RATIONALE: Hormone therapy may stop the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more cancer cells. It is not yet known which hormone therapy and chemotherapy regimen is most effective for acute lymphoblastic leukemia.

PURPOSE: Randomized phase III trial to compare the effectiveness of different steroid therapy and chemotherapy regimens in treating children who have acute lymphoblastic leukemia.


Condition Intervention Phase
Leukemia
Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: prednisolone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 1800
Study Start Date: January 1997
  Hide Detailed Description

Detailed Description:

OBJECTIVES:

  • Compare the effects of oral prednisolone vs oral dexamethasone on remission rate, event-free survival, and overall survival of children with acute lymphoblastic leukemia.
  • Compare the effect of oral mercaptopurine (MP) vs oral thioguanine (TG) on remission rate, event-free survival, and overall survival of this patient population.
  • Assess the effect of a schedule concentrating on tight control of maintenance therapy, compensating where necessary for constitutional drug resistance and avoiding poor physician or patient compliance, on event-free survival of these patients.
  • Compare the pharmacokinetics of MP and TG in these patients.
  • Collect data on the presence or absence of minimal residual disease in serial bone marrow samples to assess its clinical importance.

OUTLINE: This is a randomized, multicenter study. Patients are randomized twice during the study: prednisolone vs dexamethasone and mercaptopurine vs thioguanine. Patients are initially stratified according to risk status (standard vs intermediate vs high). Patients are stratified at the second randomization according to gender, age (under 2 years vs 2 to 9 years vs over 9 years), WBC (under 50,000/mm^3 vs over 50,000/mm^3), steroid allocation, and early response (slow vs rapid).

Patients with verified CNS disease receive weekly intrathecal (IT) methotrexate until 2 consecutive clear cerebrospinal fluid samples have been obtained. Cranial radiotherapy is administered over 15-21 days during weeks 5-8 concurrently with methotrexate IT in the appropriate regimen. Following radiotherapy, these patients receive monthly methotrexate IT for 1 year and then every 3 months until the end of therapy.

Patients with testicular infiltration receive additional radiation fractions daily for 12 days to both testes during weeks 5-8.

Regimen A (standard-risk patients)

  • Remission induction: Patients receive the assigned oral steroid (prednisolone or dexamethasone) twice a day on days 1-28; vincristine IV on days 1, 8, 15, and 22; and asparaginase IM three days a week for 9 doses beginning on day 4. Patients also receive cytarabine IT on day 1 and methotrexate IT on day 8.
  • If bone marrow is M3 at day 15 or M2 at day 29, therapy continues on regimen C. Otherwise, patient continues on regimen A.
  • Consolidation: Patients taper the assigned steroid over days 29-35, plus receive vincristine IV on day 29 and methotrexate IT on days 29, 36, 43, and 50. Patients also receive oral thiopurine (mercaptopurine or thioguanine) on days 29-56.
  • Interim maintenance I: Patients receive the assigned oral steroid twice a day on days 57-61 and 85-89 plus vincristine IV on days 57 and 85. Patients also receive the assigned oral thiopurine on days 57-105 and oral methotrexate on days 57, 64, 71, 78, 85, 92, 99, and 106.
  • Delayed intensification I: Patients receive oral dexamethasone twice a day on days 113-119 and 127-133, plus vincristine IV and daunorubicin IV over 6 hours on days 113, 120, and 127. Patients also receive asparaginase IM three days a week for 6 doses beginning on day 114 or 115 and methotrexate IT on day 113. Cyclophosphamide IV over 30 minutes is administered on day 141. Patients also receive oral thioguanine on days 141-154, cytarabine IV or subcutaneously (SC) twice a day on days 142-145 and 149-152, and methotrexate IT on days 141 and 148.
  • Interim maintenance II: Patients receive the assigned oral steroid twice a day on days 162-166 and 190-194 and vincristine IV on days 162 and 190. Patients also receive the assigned oral thiopurine on days 162-210 and oral methotrexate on days 162, 169, 176, 183, 190, 197, 204, and 211.
  • Delayed intensification II: Patients receive oral dexamethasone on days 218-224 and 239-245; vincristine IV and doxorubicin IV over 6 hours on days 218, 225, and 232; and methotrexate IT on day 218. Asparaginase IM is administered three days a week for 6 doses beginning on day 219 or 220. Patients then receive cyclophosphamide IV over 30 minutes on day 246, oral thioguanine on days 246-259, cytarabine IV or SC on days 247-250 and 254-257, and methotrexate IT on days 246 and 253.
  • Maintenance: Treatment is given as a 12-week course for 6 courses (girls) or 11 courses (boys). Patients receive the assigned oral steroid twice a day on days 1-5, 29-33, and 57-61 of each course, vincristine IV on days 1, 29, and 57 of each course, and the assigned oral thiopurine daily during each course. Methotrexate IT is administered to girls on day 1 of each course and on day 84 of course 6, while boys receive 1 dose on day 1 of course 11. Patients also receive oral methotrexate on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each course.

Regimen B (intermediate-risk patients)

  • Remission induction: Patients receive the assigned oral steroid, vincristine, and asparaginase as in regimen A remission induction. Patients also receive daunorubicin IV over 6 hours on days 1, 8, 15, and 22; cytarabine IT on day 1; and methotrexate IT on day 8.
  • If bone marrow is M3 at day 8 or M2 at day 29, therapy continues on regimen C. Otherwise, patient continues on regimen B.
  • Consolidation: The assigned steroid is tapered over days 29-35. Patients also receive cyclophosphamide IV over 30 minutes on days 29 and 43; cytarabine IV or SC on days 30-33, 37-40, 44-47, and 51-54; oral mercaptopurine on days 29-56; and methotrexate IT on days 29, 36, 43, and 50.
  • Patients with M1 or M2 bone marrow on day 64 proceed to interim maintenance I.
  • Interim maintenance I: Patients receive the assigned steroid, vincristine, the assigned thiopurine, and oral methotrexate as in regimen A. Patients also receive methotrexate IT on days 64 and 92.
  • Delayed intensification I: Patients receive oral dexamethasone on days 120-126 and 134-140, plus vincristine IV and doxorubicin IV over 6 hours on days 120, 127, and 134. Patients also receive asparaginase IM three days a week for 6 doses beginning on day 121 or 122 and methotrexate IT on day 120. Patients then receive cyclophosphamide IV over 30 minutes on day 148, oral thioguanine on days 148-161, cytarabine IV or SC on days 149-152 and 156-159, and methotrexate IT on days 148 and 155.
  • Interim maintenance II: Patients receive the assigned oral steroid twice a day on days 169-173 and 197-201; vincristine IV on days 169 and 197; the assigned oral thiopurine on days 169-217; oral methotrexate on days 176, 183, 190, 197, 204, and 211; and methotrexate IT on days 169 and 197.
  • Delayed intensification II: Patients receive oral dexamethasone on days 225-231 and 239-245; vincristine IV and doxorubicin IV over 6 hours on days 225, 232, and 239; and methotrexate IT on day 225. Asparaginase IM is administered three days a week for 6 doses beginning on day 226 or 227. Patients then receive cyclophosphamide IV over 30 minutes on day 253, oral thioguanine on days 253-266, cytarabine IV or SC on days 253-256 and 260-263, and methotrexate IT on days 253 and 260.
  • Maintenance: Treatment is administered as in regimen A.

Regimen C (Slow early response to regimen A or B OR high-risk patients)

  • Remission induction for patients switching from regimen A: Patients continue assigned oral steroid for a total of 35 days. Patients also receive vincristine IV on days 15, 22, and 29, and daunorubicin IV over 6 hours on days 15 and 22. Asparaginase IM is administered 3 days a week for 6 doses. Patients receive methotrexate IT on day 29 (patients with CNS disease also receive doses on days 15 and 22).
  • Remission induction for patients switching from regimen B: Patients continue assigned oral steroid for a total of 35 days. Patients also receive vincristine IV and daunorubicin IV over 6 hours on days 8, 15, and 22. Asparaginase IM continues three days a week for up to 6 doses. Patients also receive methotrexate IT on day 29 (patients with CNS disease also receive doses on days 14 and 21).
  • Consolidation: Patients receive cyclophosphamide IV over 30 minutes on days 36 and 64; cytarabine IV or SC on days 37-40, 44-47, 65-68, and 72-75; oral mercaptopurine on days 36-49 and 64-77; vincristine IV on days 50, 57, 78, and 85; pegaspargase IM on days 50 and 78; and methotrexate IT on days 36, 43, 50, and 57.
  • Interim maintenance I: Patients receive vincristine IV and methotrexate IV on days 99, 109, 119, 129, and 139. Pegaspargase IM is administered on days 100 and 110 and methotrexate IT is administered on days 99 and 129 (patients with CNS disease do not receive the dose on day 129).
  • Patients with M1 or M2 bone marrow proceed to delayed intensification I.
  • Delayed intensification I:

    • Reinduction: Patients receive vincristine IV and doxorubicin IV over 6 hours on days 162, 169, and 176; oral dexamethasone twice a day on days 162-168 and 176-82; methotrexate IT on day 162; and pegaspargase IM on day 165.
    • Reconsolidation: Patients receive cyclophosphamide IV over 30 minutes on day 190, oral thioguanine on days 190-203, cytarabine IV or SC on days 191-194 and 197-200, vincristine IV on days 204 and 211, and pegaspargase IM on day 204. Methotrexate IT is administered on days 190 and 197 (patients with CNS disease do not receive the dose on day 197).
  • Interim maintenance II: Patients receive vincristine IV and methotrexate IV on days 218, 228, 238, 248, and 258. Pegaspargase IM is administered on days 219 and 239. Patients also receive methotrexate IT on days 218 and 248 (patients with CNS disease do not receive the dose on day 248).
  • Delayed intensification II:

    • Reinduction: Patients receive vincristine IV and doxorubicin IV over 6 hours on days 274, 281, and 288; oral dexamethasone twice a day on days 274-280 and 288-294; methotrexate IT on day 274; and pegaspargase IM on day 277.
    • Reconsolidation: Patients receive cyclophosphamide IV over 30 minutes on day 302, oral thioguanine on days 302-315, cytarabine IV or SC on days 303-306 and 309-312, and vincristine IV on days 316 and 323.
  • Maintenance: Treatment is administered as in regimen A.

PROJECTED ACCRUAL: Approximately 1,800 patients will be accrued for this study within 6 years.

  Eligibility

Ages Eligible for Study:   1 Year to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed acute lymphoblastic leukemia (ALL)
  • No B-ALL (Burkitt-like, t(8;14), L3 morphology, SMIg positive)
  • Meets criteria for one of the following risk groups:

    • Standard risk

      • 1 to 9 years old
      • Highest WBC less than 50,000/mm^3
      • BCR-ABL negative
      • Not hypodiploid
      • No MLL gene rearrangements if 12 to 24 months old
    • Intermediate risk

      • Over 10 years old AND/OR
      • WBC greater than 50,000/mm^3
      • BCR-ABL negative
      • Not hypodiploid
      • No MLL gene rearrangement if 12 to 24 months old
    • High risk, defined by at least 1 of the following:

      • Slow early response with regimen A or B
      • BCR-ABL positive
      • Hypodiploid
      • MLL gene rearrangement and 12 to 24 months old

PATIENT CHARACTERISTICS:

Age:

  • 1 to 18

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • See Disease Characteristics

Hepatic:

  • Not specified

Renal:

  • Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • Previous treatment with HR1 regimens allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003437

Locations
United Kingdom
Oxford Radcliffe Hospital
Oxford, England, United Kingdom, 0X3 9DU
Sponsors and Collaborators
Medical Research Council
Investigators
Study Chair: C. Mitchell Oxford University Hospitals NHS Trust
  More Information

Additional Information:
Publications:
Moorman AV, Ensor HM, Chilton L, et al.: Prognostic relevance of cytogenetics in childhood acute lymphoblastic leukaemia (ALL): final results from MRC ALL97. [Abstract] Blood 114 (22): A-88, 2009.
Mitchell CD, Richards SM, Kinsey SE, et al.: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of UK MRC trial ALL97/99. [Abstract] Pediatr Blood Cancer 43 (4): A-0.082, 2004.
Roy A, Bradburn M, Moorman AV, et al.: Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. [Abstract] Blood 104 (11): A-165, 2004.
Vora A, Ward R, Payne J, et al.: Benefit of targeted intensification for NCI high risk childhood lymphoblastic leukaemia: results of the United Kingdom Medical Research Council trial ALL97 and ALL97/99. [Abstract] Blood 108 (11): A-1869, 2006.

ClinicalTrials.gov Identifier: NCT00003437     History of Changes
Other Study ID Numbers: CDR0000066464, MRC-LEUK-ALL97, EU-97032
Study First Received: November 1, 1999
Last Updated: December 3, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent childhood acute lymphoblastic leukemia
untreated childhood acute lymphoblastic leukemia

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Asparaginase
Cyclophosphamide
Daunorubicin
Dexamethasone
Doxorubicin
Liposomal doxorubicin
Methotrexate
Pegaspargase
Vincristine
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Alkylating Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antiemetics
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal

ClinicalTrials.gov processed this record on October 21, 2014